CONCORDBIO1,445.20

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹15,119 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
CONCORDBIO
FY26
BIOCON
FY26
DIVISLAB
FY26
CAPLIPOINT
FY26
Peer
Median
Valuation — at last close
P/E58.32×138.65×97.31×33.10×97.31× -40%
P/B7.50×1.73×14.89×5.84×5.84× +28%
EV/EBITDA40.02×21.73×72.47×27.26×27.26× +47%
Market Cap₹15,119 Cr₹63,381 Cr₹2.49L Cr₹21,219 Cr₹63,381 Cr -76%
Growth
Revenue CAGR 3Y14.85%10.78%14.25%14.25%
Revenue CAGR 5Y18.96%8.67%15.56%15.56%
Net Income CAGR 3Y-16.91%12.09%19.89%12.09%
Revenue YoY (latest Q)26.23%10.00%27.80%19.63%19.63% +34%
Net Income YoY (latest Q)30.96%53.36%65.50%18.79%53.36% -42%
Profitability
EBITDA Margin34.83%20.41%32.59%34.79%32.59% +7%
Net Income Margin24.57%2.18%24.32%29.71%24.32% +1%
Return on Common Equity12.95%1.05%15.32%17.66%15.32% -15%
Return on Capital Employed14.18%3.02%16.55%18.80%16.55% -14%
Return on Assets11.60%0.58%12.82%16.06%12.82% -10%
Credit & Quality
Total Debt/Equity0.00×0.40×0.00×0.00×0.00×
Interest Coverage1034.40×1.51×129.48×790.90×129.48× +699%
Scale — latest FY
Revenue / Total Income₹1,055 Cr₹16,927 Cr₹10,560 Cr₹2,187 Cr₹10,560 Cr -90%
Net Income₹259 Cr₹369 Cr₹2,568 Cr₹650 Cr₹650 Cr -60%
Total Assets₹2,235 Cr₹63,651 Cr₹20,033 Cr₹4,045 Cr₹20,033 Cr -89%
EPS₹24.78₹2.82₹96.75₹84.36₹84.36 -71%
Book Value per Share₹192.62₹225.92₹632.49₹477.74₹477.74 -60%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.